CONTACT

Isabelle CHEMIN
isabelle.chemin@inserm.fr

Philippe MERLE
philippe.merle@inserm.fr

+33 4 78 68 19 70 (secretariat)

Inserm building
151 Cours Albert Thomas
69003 LYON
FRANCE
MERLE Philippe
Co-chef d'équipe
Professeur des Universités - Praticien hospitalier (UCBL - HCL)
philippe.merle@inserm.fr
CHEMIN Isabelle
Co-chef d'équipe
DR2 Inserm
isabelle.chemin@inserm.fr
CARON DE FROMENTEL Claude
PETIT Marie-Anne
HANTZ Olivier
BROUSSOLLE Christiane
Professeur des Universités - Praticien hospitalier (UCBL - HCL)
christiane.broussole@chu-lyon.fr
DENY Paul
Professeur des Universités - Praticien hospitalier (Université Paris XIII - UFR SMBH)
paul.deny@inserm.fr
DUCERF Christian
Professeur des Universités - Praticien hospitalier (UCBL - HCL)
christian.ducerf@chu-lyon.fr
TREPO Christian
Professeur des Universités - Praticien hospitalier (UCBL - HCL)
christian.trepo@inserm.fr
GOUILLAT Christian
Professeur des Universités - Praticien hospitalier (UCBL - HCL)
christian.gouillat@chu-lyon.fr
RADENNE Sylvie
Praticien hospitalier HCL
sylvie.radenne@chu-lyon.fr
BANCEL Brigitte
Praticien hospitalier HCL
brigitte.bancel@chu-lyon.fr
BERTHILLON Pascale
Ingénieur d'étude
pascale.berthillon@inserm.fr
LEFRANCOIS Lydie
Assistante Ingénieur
lydie.lefrancois@inserm.fr
ACHAINTRE Laetitia
BERBY Françoise
BORDES Isabelle
GEROSSIER Laetitia
SAMARAKOON Natali
HALL Janet
CORTAY Jean-Claude
SABRA Mirna
Post-Doctorante
mirna.sabra@inserm.fr
GUILLOT Clément
MARTEL Nora
Post-Doctorante
nora.martel@inserm.fr
BACHELARD-CASCALES Elodie
GIFU Patricia
FARES Nadim
PEYROT Loïc
Assistant Ingénieur
loic.peyrot@inserm.fr
DELPRAT Christine
PU1, Université Claude Bernard Lyon1
christine.delprat@inserm.fr
Coordinatrice du Master Erasmus+ Mundus «Leading International Vaccinology Education»: LIVE Master website
Interactions hôte-pathogène dans les cancers humains : Host-PyV website
Membre du Conseil National des Universités (CNU65)
VALENTIN Hélène
Voir les objectifs et projets Voir les publications

Collaborations

O Andrisani (Purdue University, Indiana, USA)
T Baumaert (Inserm U748, Strasbourg, FRANCE) 
MF Bourgeade (Inserm U785, Villejuif, FRANCE)
P Hainaut (GIRC, Grenoble, FRANCE)
S Lebecque (CRCL, team "Innate Immune Signaling and Oncogenesis")
M Rivoire (CLB, Lyon, FRANCE) 
C Neveut (Institut Pasteur, Paris, FRANCE) 
R Parana (Fiocruz University, Salvadore de Bahia, BRAZIL)
M Strubin (CMU, Geneva, Switzerland)
JR Wands (Liver Research Centre, Brown University, Providence RI, USA)
F Zoulim (CRCL, team "Pathogenesis of Hepatitis B and C infections")

OBJECTIVES

Our research objectives concern the development of hepatocellular carcinoma induced or not by viruses. Experimental approaches are based on hepatic stem cells and the study of genetic/epigenetic mechanisms implicated in early stages of cancer development with particular attention on Wnt, TP53, TP73 and NFKB. Concerning the role of hepatitis B and delta we have a particular interest for the study of HBx properties and role in carcinogenesis and HBV replication. Moreover, we are developping several phylogenetic and epidemiologic studies on HBV and HDV isolates from different geographical areas where HCC incidence is high.

PUBLICATIONS

Selected publications from the team

- Decorsière A., Mueller H., van Breugel PC., Abdul F., Gerossier L., Beran RK., Livingston CM., Niu C., Fletcher SP., Hantz O., Strubin M. (2016). Hepatitis B virus X protein identifies the smc5/6 complex as a host restriction factor. Nature, 531, 386-389.

- Boudra MT., Bolin C., Chiker S., Fouquin A., Zaremba T., Vaslin L., Biard D., Cordelières FP., Mégnin-Chanet F., Favaudon V., Fernet M., Pennaneach V. and Hall J. (2015). PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels. Cell. Mol. Life Sci., 72, 1585-1597.

- Chapellier M., Bachelard-Cascales E., Schmidt X., Clément F., Treilleux I., Delay E., Jammot A., Ménétrier-Caux C., Pochon G., Besançon R., Voeltzel T., Caron de Fromentel C., Caux C., Blay JY., Iggo R. and Maguer-Satta V. (2015). Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response. Stem Cell Reports, 4, 239-254.

- Paul S., Rochereau N., Martinez P., Stratmann T., Delputte C., Delprat C., Poland GA. (2015). Answering the call for educating the new generation of vaccinologists – A new european erasmus(+) Joint Master Degree in vaccinology. Vaccine, 33, 6135-6.

- Petit M-A., Berthillon P., Pradat P., Arnaud C., Bordes I., Virlogeux V., Maynard M., Bailly F., Zoulim F., Chemin I. and Trépo C. (2015). Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. Clin Res Hepatol Gastroenterol., 39, 699-704.

- Rivière L., Gerossier L., Ducroux A., Dion S., Deng Q., Michel M-L., Buendia M-A., Hantz O. and Neuveut C. (2015). HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J. Hepatol., 63, 1093-1102.

- Villiers MB., Cortay JC., Cortès S., Bloquel B., Brichler S., Brakha C., Kay A., Falah N., Zoulim F., Marquette C., Marche PN. and Dény P. (2015). Protein/peptide arrays to detect anti-Delta genotype 1, 6, 8 specific antibodies among Hepatitis D Virus infected patients, by surface plasmon resonance imaging. J. Clin. Microbiol., 53, 1164-1171.

- Delprat C and Aricò M. (2014). Blood spotlight on Langerhans Cell Histiocytosis. Blood, 124, 867-72.

- Guillot C., Favaudon V., Herceg Z., Sagne C., Sauvaigo S., Merle P., Hall J. and Chemin I.(2014). PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. BMC Cancer, 14, 603.

- Dupinay T., Gheit T., Roques P., Cova L., Chevallier-Queyron P., Tasahsu SI., Grand RL., Simon F., Cordier G., Wakrim L., Benjelloun S., Trépo C. and Chemin I. (2013). Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island. Hepatology 58, 1610-1620.

- Olsson Åkefeldt S., Ismail MB., Valentin H., Aricò M., Henter JI. and Delprat C. (2013). Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss. Clin. Dev. Immunol., Article ID 701305.

- Pez F., Lopez A., Kim M., Wands JR., Caron de Fromentel C. and Merle P. (2013). Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J. Hepatol. 59, 1107-1117.

- Gouas DA., Villar S., Ortiz-Cuaran S., Legros P., Ferro G., Kirk GD., Lesi OA., Mendy M., Bah E., Friesen MD., Groopman J., Chemin I. and Hainaut P. (2012). TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis 33, 1219-24.

- Studach LL., Menne S., Cairo S., Buendia MA., Hullinger RL., Lefrançois L., Merle P. and Andrisani OM. (2012). A subset of Suz12/PRC2 target genes is activated during HBV replication and liver carcinogenesis associated with hepatitis B virus X protein. Hepatology 56, 1240-51.

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :